OR WAIT null SECS
Conjugated vaccines are meeting the need for longer-lasting immune responses, but the production process is complex, and manufacturers are looking for simpler solutions.
Successful vaccination programs have been recognized as key contributors to enhanced public health. In an effort to improve existing vaccine therapies, drug manufacturers are seeking technologies that will enable the production of more robust and longer-lasting immune responses. One solution has been the development of more sophisticated conjugated vaccines. The manufacturing process for these vaccines is very complex, however, and involves the synthesis of several different polysachharides and proteins and the numerous possible valences of the conjugated vaccines.
Annelies Onraedt, global market manager for vaccines with Pall Life Sciences, spoke with Cynthia Challener, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report, about the manufacturing process, recent developments that have helped improve the efficiency of the process, such as the use of chromatography rather than solvent precipitation and single-use systems for the final filling steps, and what issues remain to be addressed.
You can listen to the conversation below.